Toggle light / dark theme

Beyond 2030: David A. Kekich on Working Towards Biological Superlongevity

In “2030: Beyond the Film” Director Johnny Boston discusses the futurist FM-2030, the Coronavirus Pandemic, and a range of urgent issues in the medical, philosophical, longevity & futurist space with leading voices.

In this episode, Boston talks with David A. Kekich on why Kekich believes working towards Biological Superlongevity should be the first goal of Transhumanists and futurists.

About David A. Kekich: (from Maximum Life Foundation)
David Kekich is President/CEO of Maximum Life Foundation that focuses on aging research. In 1999, he realized the inevitability that science will someday control the human aging process. He understood human beings will someday be able to enjoy very long health spans by studying aging research, the root cause of most deadly diseases. The problem? He was in a race against the clock. He was faced with the possibility of being part of the “last generation to suffer from heart disease, cancer, Alzheimer’s and other aging related diseases”. His solution was to further that aging research and hopefully move it forward by establishing the Maximum Life Foundation.

Maximum Life Foundation Website:
https://www.maxlife.org/

About 2030 the film:
Johnny Boston was 10 years old when he first met FM-2030, a futurist who intended to live forever. But in 2000, after his body ceased to function, FM was cryonically preserved. 16 years later, an unexpected call places FM’s future in Johnny’s hands.

Directed By: Johnny Boston

David Sinclair seeks £100m for anti-aging fight

One of the world’s greatest anti-aging scientists continues his groundbreaking efforts. In the photo next to Dr David Sinclair, there is a fella who kind of looks like my friend, Dr Yuancheng Ryan Lu. Is that you? (Dr Lu has confirmed that he is indeed the scientist on the right. Dr Sinclair is on the left.)

I can’t wait to see what they develop next!


Harvard scientist David Sinclair is one of Longevity’s big hitters. Just a year after raising $50M in Series B financing, his company Life Biosciences LLC is looking for $100M to progress its anti-aging research [1].

Longevity. Technology: Life Biosciences had an original Series B goal of $25M; it doubled it. As NAD continues to embed in the anti-aging supplement marketplace, the company is looking to expand, with a range of subsidiaries under its Longevity umbrella. Although the company isn’t spilling any secrets on its proposed clinical trials, we will be sure to keep a close eye on progress.

Life Biosciences, valued last year at approximately $500M, is built on Sinclair’s experience as co-Director of the Paul F Glenn Center for the Biology of Aging at Harvard Medical School, as a genetics professor at Harvard University and on previously-founded companies Arc Bio, Genocea and Ovascience.

Lab Mice Telomeres Do Not Break Them as Disease Models

With comments from Aubrey de Grey.


Bret Weinstein was interviewed on the Joe Rogan show and Bret claimed that the breeding protocols and telomeres of lab mice are broken. Bret claims that this problem is so severe that it calls into question the safety and correctness of decades of pharmaceutical studies.

Bret wrote a paper on that in 2002 which is totally broken.

Aubrey reviewed the paper.

Breakthrough in Age Reversal With Youngblood Plasma — Dr Harold Katcher — CTO Nugenics Research

#nugencis #nugenicsresearch #humanlongevity #agereversal #blissatomic
Dr. Harold has been a pioneer in the field of cancer research, in the development of modern aspects of gene hunting and sequencing. He carries expertise in bioinformatics, chronobiology, and biotechnology and is currently working in the capacity of Chief Technical Officer at Nugenics Research Pvt Ltd. exploring in anti-aging modalities.
They recently released a paper online on #biorxiv regarding their breakthrough research on Human Age Reversal using Young Blood #plasma, the paper’s authors include recognized Longevity academician Steve Horvath.

The paper also caught the attention of #davidsinclair the leading researcher/voice in the field of Human Longevity.
Dr Katcher spoke about how & why he moved from cancer research to Human Longevity, his research & results of 54% age reversal in Rats, his partner #akshaysanghavi, the future road map/timelines on how & when this might be commercially available.

https://www.linkedin.com/in/harold-katcher-340aa78
https://www.biorxiv.org/content/10.1101/2020.05.07.082917v1
https://blissatomic.blogspot.com/

Timelines
0:25- Introduction
1:14- Approach to Reverse Aging
5:49 –Aging a Progression
8:09 — Age Reversal Experiment Results
9:59 — What is the DNA Methylation Clock
13:12 –Young Blood plasma
14:23 — Chronological Limit on Reverse Aging
17:20 — Side Effects if any on the Rats
18:07 — Nugencis Research & Biz Partner Akshay Sanghavi
20:06 — Response from Peers
22:50 — Reason to Move From pioneering Cancer Research to Aging
29:00 –Rats to Dogs & the then Human testing
30:00 — Immortal Jellyfish

The rate we acquire genetic mutations could help predict lifespan, fertility

Differences in the rate that genetic mutations accumulate in healthy young adults could help predict remaining lifespan in both sexes and the remaining years of fertility in women, according to University of Utah Health scientists. Their study, believed to be the first of its kind, found that young adults who acquired fewer mutations over time lived about five years longer than those who acquired them more rapidly.

The researchers say the discovery could eventually lead to the development of interventions to slow the .

“If the results from this small study are validated by other independent research, it would have tremendous implications,” says Lynn B. Jorde, Ph.D., chair of the Department of Human Genetics at U of U Health and a co-author of the study. “It would mean that we could possibly find ways to fix ourselves and live longer and better lives.”

CAR T cells beyond cancer: Targeting senescence-related diseases

Chimeric antigen receptor (CAR) T cells have transformed the treatment of refractory blood cancers. These genetically engineered immune cells seek out and destroy cancer cells with precision. Now, scientists at Memorial Sloan Kettering are deploying them against other diseases, including those caused by senescence, a chronic “alarm state” in tissues. The scope of such ailments is vast and includes debilitating conditions, such as fibrotic liver disease, atherosclerosis, and diabetes.

Key to the success of CAR T cell therapy has been finding a good target. The first US Food and Drug Administration-approved CAR T cells target a molecule on the surface of blood cancers called CD19. It is present on but few other , so side effects are limited.

Taking their cue from this prior work, a team of investigators including Scott Lowe, Chair of the Cancer Biology and Genetics Program in the Sloan Kettering Institute, and Michel Sadelain, Director of the Center for Cell Engineering at MSK, along with their trainees Corina Amor, Judith Feucht, and Josef Leibold, sought to identify a target on senescent cells. These cells no longer divide, but they actively send “help me” signals to the immune system.

New Horizons: Dietary protein, ageing and the Okinawan ratio

Nutrition has profound effects on ageing and lifespan. Caloric restriction is the major nutritional intervention that historically has been shown to influence lifespan and/or healthspan in many animal models. Studies have suggested that a reduction in protein intake can also increase lifespan, albeit not as dramatically as caloric restriction. More recent research based on nutritional geometry has attempted to define the effects of nutrition on ageing over a broad landscape of dietary macronutrients and energy content. Such studies in insects and mice indicate that animals with ad libitum access to low-protein, high-carbohydrate diets have longest lifespans. Remarkably, the optimum content and ratio of dietary protein to carbohydrates for ageing in experimental animals are almost identical to those in the traditional diets of the long-lived people on the island of Okinawa.

/* */